Disease relevance of Polyribosyl phosphate

• Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response [1].
• Paients who failed to develop antibody to polyribophosphate after meningitis also exhibited impaired antigen clearance [1].
• Although bacteremia cleared promptly after antibiotic therapy, circulating PRP could be detected in serum for relatively long periods, with 51% of the patients still having detectable antigen after 30 days postinfection [2].
• Groups of children (mean age, 31.4 months) with Haemophilus influenzae type b meningitis, epiglottitis, or septic arthritis were tested for the presence and levels of bacteremia, capsular polyribophosphate (PRP) antigenemia, and development of specific antibody in serum after the onset of acute illness [2].
• These antibody levels were calibrated by comparison with serum pool obtained from healthy adult volunteers, who were immunized with Hib polyribose-phosphate vaccine (Merieux) [3].

High impact information on Polyribosyl phosphate

• Polyribophosphate was regularly found in acute serum and cerebrospinal fluid samples and could be detected in unbound form for periods of 1-30 days after initiation of effective therapy [1].
• The immunodiffusion and hemagglutination inhibition tests also failed to demonstrate that the capsular material (polyribose phosphate) was in ribosomal preparations [4].
• Antibody to polyribophosphate, the capsular polysaccharide of Haemophilus influenzae type b, was measured in healthy ambulatory children by a radioactive antigen-binding assay [5].
• To investigate the basis for this defect, we measured natural IgG and IgG1-4 antibody levels to Haemophilus influenzae type b polyribophosphate (PRP) and tetanus toxoid by enzyme-linked immunosorbent assay in 24 adult CF patients and 20 normal controls [6].
• Twenty-one pregnant women were vaccinated with the polyribophosphate capsular antigen of Hemophilus influenzae, type b, at 34 to 36 weeks of gestation [7].

Chemical compound and disease context of Polyribosyl phosphate

• Clinical studies of a new latex particle agglutination test for detection of Haemophilus influenzae type b polyribose phosphate antigen in serum, cerebrospinal fluid, and urine [8].

Biological context of Polyribosyl phosphate

• Polyribophosphate levels and patterns of clearance were studied in relation to hospital course and antibody response [1].

Anatomical context of Polyribosyl phosphate

• In view of the persistent presence of type-specific capsular polysaccharide of H influenzae b (polyribophosphate [PRP]) in blood serum without any detectable anti-PRP antibody for 30 days following H influenzae b meningitis, monthly treatment with immune human serum globulin was undertaken until spontaneous production of anti-PRP antibody occurred [9].

Analytical, diagnostic and therapeutic context of Polyribosyl phosphate

• Complexes of polyribophosphate dissociable with acid and pepsin were detected in serum samples from 17 patients, in one case for a period of 145 days after hospitalization [1].
• On the other hand, bacterial counts in excess of 10(4)/ml were associated with greater than 1,000 ng of PRP per ml (r = 0.98, r2 = 0.96, P less than 0.001) [2].
• Rapid diagnosis of Haemophilus influenzae type b meningitis is possible using immunological tests for capsular antigen (polyribophosphate, PRP), such as countercurrent immunoelectrophoresis (CIE) and latex particle agglutination (LPA) [10].

References